We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neovasc Inc | NASDAQ:NVCN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.03 | 27.70 | 30.00 | 0 | 01:00:00 |
NASDAQ, TSX: NVCN
VANCOUVER, March 21, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.
Conference Call & Webcast
Wednesday, March 28th @ 4:30pm Eastern Time
Domestic: |
800-281-7973 |
International: |
323-794-2093 |
Passcode: |
4395026 |
Webcast: |
http://public.viavid.com/index.php?id=128910 |
Replays available through April 10: |
|
Domestic: |
844-512-2921 |
International: |
412-317-6671 |
Conference ID: |
4395026 |
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
Copyright 2018 Canada NewsWire
1 Year Neovasc Chart |
1 Month Neovasc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions